D-serine added to antipsychotics for the treatment of schizophrenia.
about
Glutamatergic drugs for schizophreniad-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophreniaSerine racemase binds to PICK1: potential relevance to schizophreniapLG72 modulates intracellular D-serine levels through its interaction with D-amino acid oxidase: effect on schizophrenia susceptibilityEarly-stage visual processing and cortical amplification deficits in schizophrenia.Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortexSynthesis, SAR and unanticipated pharmacological profiles of analogues of the mGluR5 ago-potentiator ADX-47273Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophreniaCircuit-based framework for understanding neurotransmitter and risk gene interactions in schizophreniaVigabatrin transport across the human intestinal epithelial (Caco-2) brush-border membrane is via the H+ -coupled amino-acid transporter hPAT1Control of Appetite and Food Preference by NMDA Receptor and Its Co-Agonist d-SerineAnti-N-methyl-d-aspartate receptor encephalitis: review of clinical presentation, diagnosis and treatmentThe impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophreniaProof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophreniaMeta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophreniaA randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophreniaAdjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacySerine racemase modulates intracellular D-serine levels through an alpha,beta-elimination activityThe involvement of N-methyl-D-aspartate receptor (NMDAR) subunit NR1 in the pathophysiology of schizophrenia.Expression of a Codon-Optimized dsdA Gene in Tobacco Plastids and Rice Nucleus Confers D-Serine Tolerance.Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.Pathogenic disruption of DISC1-serine racemase binding elicits schizophrenia-like behavior via D-serine depletion.Modeling resilience to schizophrenia in genetically modified mice: a novel approach to drug discovery.Neonatal disruption of serine racemase causes schizophrenia-like behavioral abnormalities in adulthood: clinical rescue by d-serineGenetic loss of D-amino acid oxidase activity reverses schizophrenia-like phenotypes in mice.Prepulse inhibition and genetic mouse models of schizophrenia.Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model.NMDA receptor phosphorylation at a site affected in schizophrenia controls synaptic and behavioral plasticity.Targeted disruption of serine racemase affects glutamatergic neurotransmission and behaviorWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.Clinical and biochemical study of d-serine metabolism among schizophrenia patients.Aspartate racemase, generating neuronal D-aspartate, regulates adult neurogenesis.Heterogeneity of D-Serine Distribution in the Human Central Nervous System.Serine racemase: activation by glutamate neurotransmission via glutamate receptor interacting protein and mediation of neuronal migration.Why is D-serine nephrotoxic and alpha-aminoisobutyric acid protective?Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.Novel therapeutic drugs for neuropsychiatric disordersD-serine treatment reduces cocaine-primed reinstatement in rats following extended access to cocaine self-administration.
P2860
Q24246163-0421DE62-09BC-4BA9-87AF-13CC43047068Q24294371-C35BC1D9-4F9B-4C75-9FD2-CE9CC483EE1DQ24297355-47447A04-5A8F-427F-A3D8-3D31841E6AEFQ24320365-B06953B9-44F9-441E-A232-310D3C892D7BQ24536566-65961B43-FB46-4F2C-87E0-0693264D079EQ24602550-381DF326-CF60-4091-8768-88119525E17DQ24626912-F843AA44-6854-4F4C-8642-AC9C702D90FEQ24632939-AE4F74C4-C777-473C-80DB-B113FC7C92A0Q24646206-0484AA2F-5D6C-4687-9FCF-29481FA16918Q24676147-CE9F7540-203D-4C41-8CBE-5605E69E7FD4Q26741317-ABCE9E32-054F-4ABC-AE0D-67A00E6323B7Q26801897-DB7E8E20-E19B-499E-B30B-40BD0DE9FFD0Q28081110-9B3C022C-D5D6-4850-86F8-9E8E5674F2D2Q28240120-AC48ABDA-9A60-472E-884C-54B9563CB108Q28248687-46FA07C9-5292-4672-9079-AF6106FBEB6FQ28263502-2948F345-9D22-4D11-B31B-C9B6693C0FE9Q28297813-A2C33772-92F3-4C00-B818-511AA578CC71Q28513330-48B024E5-04DA-42D5-8EAD-589FF5F6918AQ30362017-BD9F7D42-EC81-41C0-81AA-5BA12A4E9688Q30384084-501162BB-5FE4-4527-AF3D-D4884C78B41FQ30387014-6128749B-4E4D-4FCE-AFB6-E2D27CBA13AAQ30428213-55C97C04-5E34-4EF8-B699-B8872E187897Q30447828-D26041C6-5084-47FA-A2D1-CE0B03651E78Q30454958-7FA3F075-DB48-4100-88E4-E32150756963Q30455182-5187EE96-AC1F-4B14-BAF4-0E81D3C18DFDQ30477241-50C8A74A-2537-41FE-9091-2C541C65FC79Q30478270-6EAE34BE-95B7-4D21-8C6E-5DB874AF2FDFQ30479725-67161E1D-A505-4FE8-ACB8-69F8FDCB96C8Q30484119-E0B01CAB-8F62-4F1B-AD45-918D9DCE73D8Q30484413-B2D50EA8-DD13-4989-AD5D-B95F666C3A44Q33223628-C1F60CBC-A66A-429C-9F10-36F4A8E830C4Q33235110-83D7D5E4-24F8-445E-AD8E-3BDBC647F39EQ33565101-50780953-E173-4B3F-BDCF-757B32DE0791Q33733662-67EB42D0-BDBB-4A91-9023-DB7EFE64C54EQ33797251-FF26EE16-7BFF-4006-8A39-D1428FE0B524Q33838048-C23739F5-E06F-4B45-AAA7-5C8E283D07A8Q34003528-D7B15C05-6A49-4140-9FDD-3701A8C4EC47Q34013820-C1A0F900-ED83-4383-8A72-519A3703FDC5Q34018299-2467AC00-3698-438B-A53E-99AD4C9E5EABQ34036997-4039E66E-6A23-4074-84E7-DB045FB91850
P2860
D-serine added to antipsychotics for the treatment of schizophrenia.
description
1998 nî lūn-bûn
@nan
1998 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
D-serine added to antipsychotics for the treatment of schizophrenia.
@ast
D-serine added to antipsychotics for the treatment of schizophrenia.
@en
D-serine added to antipsychotics for the treatment of schizophrenia.
@nl
type
label
D-serine added to antipsychotics for the treatment of schizophrenia.
@ast
D-serine added to antipsychotics for the treatment of schizophrenia.
@en
D-serine added to antipsychotics for the treatment of schizophrenia.
@nl
prefLabel
D-serine added to antipsychotics for the treatment of schizophrenia.
@ast
D-serine added to antipsychotics for the treatment of schizophrenia.
@en
D-serine added to antipsychotics for the treatment of schizophrenia.
@nl
P2093
P1476
D-serine added to antipsychotics for the treatment of schizophrenia.
@en
P2093
P304
P356
10.1016/S0006-3223(98)00279-0
P407
P577
1998-12-01T00:00:00Z